
OIG adds to increased scrutiny of how patients pay for rising share of drug costs
May 27th, 2014 - Scott KraftCharity programs that help patients pay for the rising cost-sharing obligations of needed drugs may run afoul of anti-kickback rules when the charity’s scope is so narrow that it guides the patient toward specific drugs for treatment or providers, the HHS Office of Inspector General said last week.
The OIG’s Supplemental Special Advisory Bulletin for Independent Charity Assistance Programs makes clear that the OIG still believes that properly structured patient assistance programs (PAPs) can help patients to afford costly new drug treatments.
The key is that financial contributions made to these charity programs by drug manufacturers and others are made to bona fide charitable programs, including those that operate independently and that the scope of the charity’s efforts around a particular disease or disease treatments are not so narrow that the funds end up being directly primarily to specific drugs.
This could include, according to the OIG, directing patients to specific providers under the belief that the patients would be given specific drugs.
Put plainly, what the OIG wants to avoid is pharmaceutical companies funneling money through charity organizations in a way that ensures most or all of the charitable funds are directed toward the patient’s share of a drug treatment, while the federal government continues to pay for its portion of the drug.
The biggest implication for the physician’s office is an indirect one – those who prescribe the same company’s drug and, as a result, have additional patients referred by a charity supported by that drug’s manufacturer, may get swept up in the added scrutiny of the OIG. Though, to be clear, the OIG’s primary target is the donor.
Private payers also trying to crack down
The strictness of the anti-kickback laws have helped to shield Medicare and Medicaid from the increasing efforts of drug manufacturers to increase use of costly drugs by heavily subsidizing the patient’s cost.
The typical method is a prescription discount card issued to the patient to use to defray the cost of the copay. The card is sometimes issued by the prescribing provider, or obtained through the drug company’s web site or other marketing effort.
A card could offer the patient, for example, a discounted copay of $20 for a drug that the insurance company has in the most expensive tier of its formulary. Hypothetically, a drug might cost $700 a month, with the patient expected to pay $70 of that cost. The drug company discounts the patient’s copay to $20, but the insurance company continues to pay its full share.
As the insurance companies increasingly see it, these efforts thwart the whole purpose of the tiered formulary, which is to incentivize the patient to seek lower cost treatment opportunities.
UnitedHealthcare backed away from an effort earlier this year to outright disallow the use of copay reduction cards or coupons for its insured patients, amid complaints from providers and pharmacies that the ban would be very difficult to enforce. Not to mention patient pressures.
Don’t expect insurance companies to give up, which may ultimately change the way patients seek drugs for treatment and the way providers prescribe. Drug companies are already pushing patients to move toward prescription delivery by mail, in some cases offering the patient a better deal, such as access to a 90-day supply at a lower cost or automated refill delivery.
As drug vendors continue to create and push more expensive drugs, expect this struggle to continue, as CMS and private insurers alike face enormous pressure to cover any drug approved by the FDA for therapeutic benefit to patients.
###
Questions, comments?
If you have questions or comments about this article please contact us. Comments that provide additional related information may be added here by our Editors.
Latest articles: (any category)
Reporting Modifiers 76 and 77 with ConfidenceApril 18th, 2023 - Aimee Wilcox
Modifiers are used to indicate that a procedure has been altered by a specific circumstance, so you can imagine how often modifiers are reported when billing medical services. There are modifiers that should only be applied to Evaluation and Management (E/M) service codes and modifiers used only with procedure codes. Modifiers 76 and 77 are used to identify times when either the same provider or a different provider repeated the same service on the same day and misapplication of these modifiers can result in claim denials.
Five Documentation Habits Providers Can Use Implement to Improve Evaluation & Management (E/M) ScoringApril 11th, 2023 - Aimee Wilcox
Provider education on E/M coding updates is vital to the success of any organization, but how do you whittle down the massive information into bite-sized pieces the providers can learn in just a few minutes? Check out the five steps we have identified to teach providers in just a few minutes that can significantly impact and improve coding outcomes.
Second Quarter 2023 Updates are Different This YearApril 6th, 2023 - Wyn Staheli
The second quarter of 2023 is NOT business as usual so it is important to pay attention to ensure that organizational processes and training take place to avoid mistakes. Not only have ICD-10-CM coding updates been added to the usual code set updates (e.g., CPT, HCPCS, ICD-10-PCS), but the end of the COVID-19 Public Health Emergency will bring about changes that will also take place during the quarter (but not on April 1, 2023.
7 Measures Developed by the HHS Office of Inspector General (OIG) to Identify Potential Telehealth FraudMarch 28th, 2023 - Aimee Wilcox
A recent review of telehealth services reported in Medicare claims data during the pandemic where these seven measures for identifying suspected fraud, waste, and abuse were applied, revealed more than a thousand Medicare providers potentially committed fraud during this period. What are the measures the OIG applied during their review, and how will that impact future telehealth guidelines moving forward?
MUEs and Bilateral IndicatorsMarch 23rd, 2023 - Chris Woolstenhulme
MUEs are used by Medicare to help reduce improper payments for Part B claims. This article will address the use of the National Correct Coding Initiative (NCCI) and Medically Unlikely Edits (MUEs) and how they are used by CMS.
It is True the COVID-19 PHE is ExpiringMarch 16th, 2023 - Raquel Shumway
The COVID-19 PHE is Expiring, according to HHS. What is changing and what is staying the same? Make sure you understand how it will affect your practice and your patients.
Billing Process FlowchartMarch 2nd, 2023 -
The Billing Process Flowchart (see Figure 1.1) helps outline the decision process for maintaining an effective billing process. This is only a suggested work plan and is used for demonstration purposes to illustrate areas which may need more attention in your practice’s policies and...